Reporting from the American Society of Clinical Oncology
Our Research Communications & Engagement Officer, Arshiya, shares some of the most exciting results from the American Society of Clinical Oncology (ASCO) conference
Nivolumab fails to meet its target
Nivolumab, an immunotherapy drug, has been unsuccessful in improving overall survival in a phase 3 clinical trial when tested in newly diagnosed glioblastoma with unmethylated MGMT
Researchers discover a new target for immunotherapy
Researchers design immune cells to target a protein found on two thirds of glioblastomas, the most common and lethal primary brain tumour
New phase 2 clinical trial testing immunotherapy drug announced
A phase 2 clinical trial testing an immunotherapy drug called ipilimumab to treat patients with glioblastomas has been announced in the United Kingdom
Immunotherapy drug shows lack of promise in Phase 3 clinical trial for glioblastoma patients
Last week Bristol-Myers Squibb announced the initial results from their Phase 3 clinical trial that was assessing the effectiveness and safety of the immunotherapy drug Nivolumab in patients with recurrent glioblastoma.
Immunotherapy and gene therapy double attack against glioblastoma shows therapeutic potential
A combinatorial approach using immunotherapy and gene therapy has been explored by researchers at the University of Michigan against the highly aggressive brain tumour, glioblastoma (GBM).
New Zealand tech firm produce virtual reality cancer immunotherapy visualisation
New Zealand-based technology company, Genulin Interactive, have produced a cutting-edge visualisation of cancer immunotherapy.